A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol (2022)
Attributed to:
A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.60424
Publication URI: https://www.repository.cam.ac.uk/handle/1810/313318
Type: Journal Article/Review
Volume: 24
Parent Publication: Trials
Issue: 1